Literature DB >> 6321679

Intramedullary spinal cord metastases from small cell carcinoma of the lung.

K C Murphy, R Feld, W K Evans, F A Shepherd, R Perrin, A A Sima, P Y Poon.   

Abstract

Four patients with intramedullary spinal cord metastases from small cell carcinoma of the lung (SCCL) are described, with emphasis on clinical presentation and treatment. All patients developed the Brown-Séquard syndrome due to intramedullary tumor in the cervical spinal cord, three within 2 mo after combined modality treatment using chemotherapy and radiotherapy. One patient presented with a Brown-Séquard syndrome and an extradural spinal cord compression from tumor. The radiological and cerebrospinal fluid findings are presented and discussed. Radiation treatment was administered to the involved segments of spinal cord in each patient. All patients responded; two for 3 and 7 mo, two for 3 and 4 wk, respectively. There was significant improvement in the quality of life for three of the four patients.

Entities:  

Mesh:

Year:  1983        PMID: 6321679     DOI: 10.1200/JCO.1983.1.2.99

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  3 in total

1.  Intramedullary spinal cord metastasis following a slowly progressive course.

Authors:  J H Koelman; M De Visser; J A Kuster; J J Dreissen; J Valk; P A Koster
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

2.  Intramedullary spinal cord metastases: a single-institution experience.

Authors:  Sung Sook Lee; Min Kyoung Kim; Sun Jin Sym; Sang Wee Kim; Woo Kun Kim; Sung-Bae Kim; Jin-Hee Ahn
Journal:  J Neurooncol       Date:  2007-02-20       Impact factor: 4.506

3.  Surgical Treatment of Spinal Cord Compression Caused by Metastatic Small Cell Lung Cancer: Ten Years of Experience in a Single Center.

Authors:  Xin Gao; Kun Zhang; Shuang Cao; Shuming Hou; Tao Wang; Wen Guo; Zheyu Wu; Qi Jia; Tielong Liu; Jianru Xiao
Journal:  Cancer Manag Res       Date:  2020-05-19       Impact factor: 3.989

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.